MediWound
42 Ha'Yarkon Street
Yavne
Tel: 972-8-9324010
Fax: 972-8-9324011
185 articles about MediWound
-
MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
9/16/2020
MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its recently submitted Biologics License Application (BLA) for NexoBrid ® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal
-
MediWound to Present at Upcoming Investor Conferences in September
9/3/2020
MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, MediWound’s Chief Executive Officer, will present at the following investor conferences in September: 2020 Wells Fargo Virtual Healthcare Conference Date: September 10, 2020 Time: 8:40am ET Format: Virtual Presentation H.C. W
-
BioSpace Global Roundup, Aug. 27
8/27/2020
Biopharma and life sciences companies from around the globe share updates on their business practices and pipelines. -
MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness
8/25/2020
MediWound Ltd. and its U.S. commercial partner Vericel Corporation announced that the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has accepted the first shipment of NexoBrid® as part of its mission to build national preparedness for public health emergencies.
-
MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update
8/6/2020
MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced financial results for the second quarter ended June 30, 2020 and provided business and financial updates related to the COVID-19
-
MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020
7/28/2020
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the second quarter ended June 30, 2020 at 7:00 am Eastern Time on Thursday, August 6, 2020. Following the release, MediWound's management will host a conference call and live webcast on Thursday, August 6, 202
-
MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns
6/30/2020
MediWound Ltd. announced it has submitted a Biologics License Application to the U.S. Food and Drug Administration seeking the approval of NexoBrid® for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
-
MediWound Reports First Quarter 2020 Financial Results and Provides Corporate UpdateEscharEx U.S. Phase 2 Study Resumed Patient Screening
5/20/2020
MediWound Ltd., a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced financial results for the first quarter ended March 31, 2020 and provided business and financial updates related to the COVID-19 pandemic.
-
MediWound to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 20, 2020
5/13/2020
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the first quarter ended March 31, 2020 at 7:00 am Eastern Time on Wednesday, May 20, 2020. Following the release, MediWound's management will host a conference call and live webcast on Wednesday, May 20, 2020 a
-
MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements
5/4/2020
MediWound Ltd. announced the expansion of its NexoBrid® European presence with distribution agreements granting GENFA MEDICA SA, its distributer in Russia, Ukraine and the Baltic countries, the exclusive right to market and distribute NexoBrid in France and Switzerland and Specialty Therapeutics PC the exclusive right to market and distribute NexoBrid in Greece, Bulgaria, Malta and Cyprus.
-
MediWound Strengthens Board of DirectorsCompany Announces Appointments of Samuel Moed and David Fox Chairman Stephen T. Wills Named Executive Chairman
4/27/2020
MediWound Ltd., a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced the appointments of Mr. Samuel Moed and Mr. David Fox to its Board of Directors to serve until the 2020 annual meeting of shareholders.
-
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
-
MediWound Provides Corporate Update Related to COVID-19 Pandemic
3/30/2020
MediWound Ltd., a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, provided an update on certain impacts of the COVID-19 pandemic on its business operations and clinical programs.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.
-
BARDA Upsizes its Contract with MediWound Awarding an Additional $5.5 Million for Emergency Readiness for NexoBrid DeploymentTotal non-dilutive funds for NexoBrid now valued at over $200 million
3/3/2020
MediWound Ltd. announced that the U.S. Biomedical Advanced Research and Development Authority has expanded its awarded contract with MediWound providing supplemental funding of $5.5 million to support emergency readiness for NexoBrid deployment upon request of use of NexoBrid in mass casualty situation.
-
BARDA Initiates the Procurement of NexoBrid for Emergency Response
1/6/2020
MediWound Ltd. and its U.S. commercial partner Vericel Corporation announced that the U.S. Biomedical Advanced Research and Development Authority within the Assistant Secretary for Preparedness and Response, a part of the U.S. Department of Health and Human Services, has begun procuring NexoBrid® for emergency stockpile as part of the HHS mission to build national preparedness for public health medical emergencies.
-
MediWound Continues NexoBrid’s Global Expansion Through a New Distribution Agreement in Australia, New Zealand and Singapore with Balance Medical
1/2/2020
MediWound Ltd. announced the signing of a distribution agreement granting Balance Medical Pty Ltd. the exclusive rights to market and distribute NexoBrid® in Australia, New Zealand and Singapore for the treatment of severe burns.
-
Clinical Catch-Up: December 2-5
12/9/2019
It was, as usual, a pretty busy week in clinical trial news. Here’s a look. -
MediWound Reports Third Quarter 2019 Financial Results
11/14/2019
Initiated U.S. NexoBrid expanded access treatment (NEXT) protocol, with plans on track for NexoBrid® BLA filing in the second quarter of 2020
-
Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns
5/7/2019
Vericel Corporation announced that it has entered into exclusive license and supply agreements with MediWound Ltd. to commercialize NexoBrid® in North America. NexoBrid is a topically-administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within four hours of application without harming viable tissue.